Prostate Neoplasm

Oncology·MeSH: Prostatic Neoplasms

Prevalence

256.0 / 100K

Incidence

111.0 / 100K/yr

23 drugs in development·7 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
Cetrelimab	KYNTRA BIO INC. (KYNB)
Darolutamide	ARS Pharmaceuticals, Inc. (SPRY)
Enzalutamide	Myovant Sciences Ltd. (MYOV)
pasritamig	GH Research PLC (GHRS)

Phase 2(3)

Phase 1(15)

Drug	Company
Apalutamide	Janux Therapeutics, Inc. (JANX)
Apalutamide	Merus N.V. (MRUS)
Cabazitaxel	Royalty Pharma plc (RPRX)
Cabazitaxel	Merus N.V. (MRUS)
Cabazitaxel	ARS Pharmaceuticals, Inc. (SPRY)
Cabazitaxel	Myovant Sciences Ltd. (MYOV)
Cetrelimab	Myovant Sciences Ltd. (MYOV)
Cetrelimab	ARS Pharmaceuticals, Inc. (SPRY)
Enzalutamide	Janux Therapeutics, Inc. (JANX)
jnj-101556143	GH Research PLC (GHRS)
JNJ-78278343	KYNTRA BIO INC. (KYNB)
JNJ-78278343	Myovant Sciences Ltd. (MYOV)
JNJ-78278343	ARS Pharmaceuticals, Inc. (SPRY)
JNJ-78278343	Royalty Pharma plc (RPRX)
JNJ-78278343	Merus N.V. (MRUS)

Phase 4(1)

Drug	Company
Enzalutamide	Royalty Pharma plc (RPRX)

BioSniper tracks 23 drugs in development for Prostate Neoplasm across 7 companies.

There are 4 clinical trials targeting Prostate Neoplasm tracked by BioSniper.

The estimated prevalence of Prostate Neoplasm is approximately 256.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.